Skip to content

Annexon ANNX Return on equity

Return on equity at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
14.5%-1.4pp
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-28.6%+3.2pp
Vor Biopharma logo
Vor BiopharmaVOR
-125.4%+671pp
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-44%+26.2pp
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-53.6%-22.6pp
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-343.8%-1,012pp

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Calculated from Annexon’s reported figures.

Based on trailing twelve months.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's return on equity?
Annexon (ANNX) reported return on equity of -87.6% in Q1 2026.
How has Annexon's return on equity changed year-over-year?
Annexon's return on equity decreased by 32.5% year-over-year, from -66.1% to -87.6%.
What is the long-term trend for Annexon's return on equity?
Over 4 years (2021 to 2025), Annexon's return on equity has grown at a 16.0% compound annual growth rate (CAGR), from -45.2% to -81.9%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.